top of page

Search


What Q1 Reveals About Biotech Leadership and Decision Avoidance
Q1 as a moment of clarity for biotech leadership Q1 is often described as the most demanding quarter in biotech. Funding expectations become explicit. Milestones are suddenly close. Time feels more expensive than it did a few weeks earlier. 👉 But Q1 is not valuable because it creates pressure . It is valuable because it creates clarity. 👉 What Q1 does better than any other moment in the year is reveal how leadership actually works . Not in theory. Not in slide decks. In rea

Attila Foris
Jan 55 min read


What Q4 Reveals About Biotech Leadership Drift
👉 By the time you reach Q4, the story usually feels familiar: timelines stretched, BD slowed, the board wants “one more layer of clarity,” and your team is working harder but somehow not moving faster. The uncomfortable truth is that Q4 doesn’t create these issues. 👉 Q4 exposes the drift that began in Q1 and that biotech leadership never fully confronted. Founders often walk into the year with conviction. But by the end of Q1, the first tradeoffs are already avoided. By Q2

Attila Foris
Dec 22, 20254 min read


From Mirror to Market: The Shift Every Biotech Growth Strategy Needs to Succeed
Scientific success does not equal commercial success. A new therapeutic platform for a rare disease. Strong in vivo results. A team spun out from a university with fresh Series A funding. Everything looks right on paper, but suddenly, everything stalls. 👉 Investors stop replying. Clinical CROs delay conversations. Strategic partners go silent after initial calls. This is where many biotech founders face a harsh truth: scientific validation is not the same as market validati

Attila Foris
Nov 5, 20255 min read


From Startup to Scale-Up: How to Overcome Biotech Scale-Up Challenges
👉 Scaling up is the critical inflection point for any biotech company. While achieving early success as a startup is a significant...

Attila Foris
Sep 24, 20257 min read


Strategy Before Tactics: The Step Most Biotech Startups Skip
Biotech founders are doers by necessity. The clock is ticking, the science is demanding, and the runway is already shrinking. Pitch...

Attila Foris
Sep 3, 20256 min read


Clarity Beats Certainty: The Strategy Advantage in Early-Stage Biotech
In Biotech, Certainty Is a Mirage Scientific training primes founders to seek certainty . Hypothesize, experiment, validate — it’s a...

Attila Foris
Aug 27, 20254 min read


From Delegation to Strategy: The Hidden Key to Scaling Biotech Startups
Delegation as a Growth Tool Every biotech startup eventually reaches a breaking point. In the earliest days, the founder often wears...

Attila Foris
Aug 25, 20256 min read


How to Keep Your Biotech Startup Competitive Amid Rapid Tech Change
If your company still operates the same way it did three years ago, you’re already behind. The pace of change in biotech has never been...

Attila Foris
Aug 18, 20253 min read


From Lab to Leadership: Shaping a Scalable Biotech Founder Mindset
Most biotech startups aren’t killed by bad science. They’re quietly suffocated by their founder’s mindset . This isn’t a personality...

Attila Foris
Aug 14, 20255 min read


How to Attract Top Biotech Talent Before Your Competitors Do
If you’ve been searching for months to hire a scientist, regulatory lead, or business development partner — but keep getting average or...

Attila Foris
Aug 6, 20253 min read
bottom of page
